Skip to main content
. 2023 Sep 7;52(5):102. doi: 10.3892/ijmm.2023.5305

Figure 6.

Figure 6

CircPDLIM5 inhibits oncogenic progression of HCC827-OR cells in terms of proliferation, migration and angiogenesis. The presence of circP-DLIM5 was (A) validated by reverse transcription-quantitative PCR in HCC827 and HCC827-OR cells, followed by (B) Sanger sequencing. (C) Expression of circPDLIM5 in HCC827-OR cells was inhibited by specific siRNAs. (D) Cell Counting Kit 8 and (E) colony formation assays were used to evaluate the cell proliferation of circPDLIM5-depleted HCC827-OR cells treated with or without osimertinib (1 µM). (F) Detection of changes in cell migration in response to osimertinib in transfected HCC826-OR cells. (G) Measurement of tube formation in human umbilical vein endothelial cells to analyze whether circPDLIM5 has an impact on the use of osimertinib in HCC827-OR cells. *P<0.05 and **P<0.01 vs. HCC827 or as indicated. NC, negative control; ns, not significant; si, small interfering.